Semaglutide linked to 26% lower 5-year predicted dementia risk
Summary
A study finds that Semaglutide, a drug for diabetes and weight loss, is associated with a 26% lower predicted risk of dementia over a 5-year period.
Similar Articles
Routine vaccines may cut dementia risk—experts have startling hypothesis on how
Routine vaccines like those for flu, shingles, and Tdap are linked to lower dementia risk, with a new hypothesis suggesting they may train the innate immune system, previously thought untrainable, offering potential new avenues for dementia prevention.
Study links GLP-1 drugs to bigger jump in women's employment than a degree
A study finds that GLP-1 drugs are associated with a larger increase in women's employment rates than obtaining a college degree.
Midlife Vascular Risk Burden and Dementia-Free Survival Years
A medical study examining how midlife vascular risk burden affects dementia-free survival years, providing insights into preventative health measures.
GLP-1 drugs led to weight loss and reversed depression-like behavior in mice
A study from Southeast University found that GLP-1 drugs like Ozempic reverse depression-like behavior in mice by promoting growth of Lactobacillus delbrueckii, which produces endocannabinoids that reduce stress effects.
@EricTopol: Reduction of cardiovascular events with tirzepatide (Zepbound) vs sitagliptin (Januvia) in people with diabetes and pri…
Eric Topol highlights a BMJ study showing tirzepatide (Zepbound) reduces cardiovascular events, infections by 36%, and all-cause mortality by 45% compared to sitagliptin in diabetic patients with prior atherosclerotic cardiovascular disease.